Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | PTPRC | P08575 | 1/20 | 0.54 |
| ▸ | PTPRG | P23470 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12581571 | 0.89 | APEX1 (0.65) | MRGPRX4ARAPEX1CYP1A2CYP2C9 | |
| SCHEMBL693069 | 0.87 | RXRA (0.57) | MRGPRX4ARNR4A2PTPRCPTPRG | |
| SCHEMBL15819764 | 0.87 | SIRT2 (0.58) | MRGPRX4ARAPEX1NR4A2PTPRG | |
| SCHEMBL30198674 | 0.86 | APEX1 (0.65) | MRGPRX4ARAPEX1NR4A2CYP1A2 | |
| SCHEMBL3889076 | 0.86 | APEX1 (0.65) | MRGPRX4ARAPEX1NR4A2CYP1A2 | |
| SCHEMBL6840369 | 0.84 | RXRA (0.54) | MRGPRX4ARAPEX1PTPRCPTPRG | |
| SCHEMBL6347118 | 0.83 | SMN1; SMN2 (0.60) | MRGPRX4ARAPEX1CYP1A2CYP2C9 | |
| SCHEMBL11565647 | 0.80 | AR (0.64) | MRGPRX4ARNR4A2PTPRCPTPRG | |
| SCHEMBL45393 | 0.79 | NPC1 (0.56) | MRGPRX4ARAPEX1CYP1A2CYP2C9 | |
| SCHEMBL18304405 | 0.78 | APEX1 (0.51) | MRGPRX4ARAPEX1NR4A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | MRGPRX4 2781/4885AR 2451/4885APEX1 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.